Jacobs Levy Equity Management, Inc 89bio, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 130,894 shares of ETNB stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130,894
Previous 45,664
186.65%
Holding current value
$1.17 Million
Previous $365,000
165.21%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ETNB
# of Institutions
163Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$136 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$127 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$71.6 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$66.1 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$62.9 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $417M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...